Tech
nology
Products
In vitro screening tools
Air³Gel
Gut³Gel
Vag³Gel
Bac³Gel
Growth Boosters
Gut³Beads
Ab
out
Con
tact
Book a Call
Book a Call
0
Air³Gel

Air3Gel

Air3Gel is a ready-to-use 3D in vitro model of human airway mucus, designed for high-throughput drug permeability testing and microbiota culture, enabling reliable efficacy assessments.

Physiologic

Native-like airway mucus model mimicking the composition and viscosity of healthy human airway mucus

Composed of:​

  • 20.0 mg/ml mucin​
  • 4.78 mg/ml NaCl​
See more

Cystic Fibrosis

Disease-specific airway mucus model replicating the thicker, more viscous mucus and higher salinity of cystic fibrosis patients.​

Composed of:​

  • 25.0 mg/ml mucin
  • 7.01 mg/ml NaCl
See more
Physiologic Air3Gel​
Physiologic Air3Gel​
No items found.

Physiologic Air3Gel​

Physiologic

Physiologic

Native-like airway mucus model mimicking the composition and viscosity of healthy human airway mucus

350.00 € *

*No VAT included

-
+
Buy now
Cystic Fibrosis Air3Gel​
Cystic Fibrosis Air3Gel​
Cystic Fibrosis Air3Gel​
Cystic Fibrosis Air3Gel​
No items found.

Cystic Fibrosis Air3Gel​

Cystic Fibrosis

Cystic Fibrosis

Disease-specific airway mucus model replicating the thicker, more viscous mucus and higher salinity of cystic fibrosis patients.​

350.00 € *

*No VAT included

-
+
Buy now

Advantages​

For different purposes

Drug permeability studies, bacterial colonization research, microbiota growth, targeted evaluation of drug efficacy for intestinal applications, and microbiome mining​

Ethical & Regulatory Advantages

Reduce the need for animal testing by mimicking human mucus, aligning with ethical and regulatory principles​

Physiologically Relevant Mucus Models

Replicates the natural composition and properties of intestinal mucus​

High-Throughput & Ready-to-Use

Standardized, reproducible, and ready-to-use mucus models that accelerates high-throughput drug and microbiome research and seamlessly integrates into existing workflows—saving time and streamlining discovery​

Publications

O.V. Garbero, L. Sardelli, C.S. Butnarasu, E. Frasca, C. Medana, F. Dal Bello, S. Visentin. Tracing the path of Quorum sensing molecules in cystic fibrosis mucus in a biomimetic in vitro permeability platform. Scientific Reports, 2024, 14(1): 25907.​

​C.S. Butnarasu, O.V. Garbero, P. Petrini, L. Visai, Sonja Visentin. Permeability Assessment of a High-Throughput Mucosal Platform. Pharmaceutics, 2023, 15(2):380.

​C.S. Butnarasu, P. Petrini, F. Bracotti, L. Visai, G. Guagliano, A. Fiorio Pla, E. Sansone, S. Petrillo, S. Visentin. Mucosomes: Intrinsically Mucoadhesive Glycosylated Mucin Nanoparticles as Multi-Drug Delivery Platform. Advanced Healthcare Materials, 2022, 11(15): e2200340.​

​D. P. Pacheco, F. Bertoglio, C.S. Butnarasu, N. Suárez Vargas, G. Guagliano, A. Ziccarelli, F. Briatico-Vangosa, V. Ruzzi, S. Buzzaccaro, R. Piazza, S. van Uden, E. Crotti, S. Visentin, L. Visai, P. Petrini. Heterogeneity Governs 3D-Cultures of Clinically Relevant Microbial Communities. Advanced Healthcare Materials, 2023.​

​D. P. Pacheco, C.S. Butnarasu, F. Briatico-Vangosa, L. Pastorino, L. Visai, S. Visentin, P. Petrini. Disassembling the complexity of mucus barriers to develop a fast screening tool for early drug discovery. Journal of Materials Chemistry B. 2019, 7, 4940-4952.​ ​

C.S. Butnarasu, N. Barbero, D. P. Pacheco, P. Petrini, S. Visentin. Mucin binding to therapeutic molecules: The case of antimicrobial agents used in cystic fibrosis. Int J Pharm, 2019, 564:136-144.​ ​

C.S. Butnarasu, G. Caron, D. P. Pacheco, P. Petrini, S. Visentin. Cystic Fibrosis Mucus Model to Design More Efficient Drug Therapies. Mol Pharm, 2022, 19(2): 520-531.​ ​

​L. Pedersoli, S. Zhang, F. Briatico-Vangosa, P. Petrini, R. Cardinaels, J. den Toonder, D. P. Pacheco. Engineered modular microphysiological models of the human airway clearance phenomena. Biotechnol Bioeng, 2021, 118(10): 3898-3913.​